{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-067170","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2023-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.431047+00:00","generated_at":"2026-06-14T08:25:58.553896+00:00","sec_items":["1.01","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HOOKIPA Pharma prices $50M public offering of common & convertible preferred stock","bullets":["Priced 22,900,768 shares of common stock at $1.31/share and 15,268 Series A-2 convertible preferred shares at $1,310/share.","Gross proceeds of $50M; net proceeds expected ~$46.3M after underwriting discounts and expenses.","Offering expected to close June 5, 2023; joint book-runners are SVB Securities and RBC Capital Markets.","Each Series A-2 preferred share converts into 1,000 common shares, non-voting, with a beneficial ownership cap of 9.99%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-067170","json":"https://secwatch.observer/filing/0001104659-23-067170.json","markdown":"https://secwatch.observer/filing/0001104659-23-067170.md","text":"https://secwatch.observer/filing/0001104659-23-067170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923067170/0001104659-23-067170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923067170/tm2317399d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T08:25:58.553896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"280d2d6f21421b0661aa79e2dfda16d40615f2c3","claim":"HOOKIPA Pharma Inc.: Filed Certificate of Designation creating Series A-2 Convertible Preferred Stock (effective 2023-06-01).","evidence_excerpt":"On June 1, 2023, the Company filed a Certificate of Designation of Series A-2 Convertible Preferred Stock with the Delaware Secretary of State","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923067170/0001104659-23-067170-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-06-01"}],"fact_type":"governance_change"},{"claim_id":"335d0d90141212a6a36fb6e77e9d87b9e2c68b8b","claim":"HOOKIPA Pharma Inc. entered into Underwriting Agreement with SVB Securities LLC and RBC Capital Markets, LLC valued at $46.3 million (effective 2023-05-31).","evidence_excerpt":"On May 31, 2023, HOOKIPA Pharma Inc., a Delaware corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the underwriters listed on Schedule A thereto","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1760542/000110465923067170/0001104659-23-067170-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"SVB Securities LLC and RBC Capital Markets, LLC"},{"label":"Value","value":"$46.3 million"},{"label":"Effective","value":"2023-05-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}